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A B S T R A C T
The prospect of cryopreservation of cellular components in the low and medium income (poor economics) part
of the world absolutely needs a solid and sustainable infrastructure to build on in line with science, technology
and globalization, based on rational thinking, standardization and harmonization of future advances we are
currently witnessing in limited parts of the world. With the stepwise development of the healthcare stimulated
by the 2012 UN Universal Health Coverage (UHC) program and supported by WHO Model List of Essential
Medicines (EM) and Essential in vitro Diagnostics (ED), a slowly growing number of countries will reach a point
where quality cryopreservation of cellular components becomes feasible as an advance for implementing specific
health care visions, policies and strategies in line with the Sustainable Development Goals 2016–2030.
1. Introduction
Steven Pinker in his 2018 book ‘Enlightenment Now; the case for
Reason, Science, Humanism and Progress’ [1] argues strongly for the
positive and visible progress noticeable in the world over the past two
to three centuries since the early development of the enlightenment in
Europe during the end of the 17th and the 18th Centuries. Despite the
still prominently existing differences in many existential, science,
economy, health and equality aspects of human life, there is a con-
tinuous lifting of the baselines for comparison over time. The poor are
no longer the poor they were a century ago, not only in terms of wealth
and financial welfare, but also in terms of knowledge, health status and
inequality. However, the more advanced part of the world progresses in
a different pace and with a different prioritizing of life and environ-
mental issues than the less developed part of the world. Unfortunately
this last part houses over three times more people than the advanced
part does.
Developments that took place in the second half of the 20 st
Century, decolonizing large parts of Africa, South and Middle America,
Asia, the Western Pacific and the Middle East, created major changes
within humanity. Also at the end of the 20 st Century the dismantling of
the Soviet Union with the fall of the Berlin wall and the creation of a
dozen so called Newly Independent States triggered a landslide in
environmental circumstances initiating major changes in life style,
wealth, health and developmental progress to which the advances in
information and communication technology (ICT) and the easing of
moving and travelling around in the world (including migration) have
largely contributed. There is a growing exchange and sharing of ex-
periences and knowledge, science and education contributing to the
continuum of baseline uplifting, challenging the need for reappraising
and redefining terminology and related philosophies, visions and ob-
servational interpretations of progress. In general the poor do not grow
poorer although the rich grow richer all over the world. Actually the
poor are slowly growing richer in many though not all aspects of life,
not in the least in the improvements of standards of living [1].
An important aspect of achieving progress is in the complexity of
the necessary infrastructural composition of a society in which people
are spending their life. Infrastructure in its multifaceted appearance de
facto serves as the fundament of existence of which the manifold of
aspects and elements is anchored in the 1948 UN Universal Human
Rights Declaration [2]. This includes besides e.g., shelter, safety, justice
and education also health and access to health care, of which blood
transfusion ‘vein-to-vein’ in all its various appearances and practices is
an integral part.
Developments and progress, advances and improvements find a
major source in knowledge and science, technology and globalization
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based on rational thinking and foreseeing implementation in a huma-
nistic environment and scenery, applicable, accessible and affordable
for all. The economics of the creation, development, maintenance and
sustainability of such environment and scenery parallel the UNDP and
World Bank classification of development – low, lower- and higher-
middle, and high human development – index or income. [3,4] Both
classifications are widely used, though essentially different. Assignment
of a World Bank group is based on Gross National Income (GNI) per
capita (current US$). The Human Development Index (HDI) is a sta-
tistical tool used to measure a country's overall achievement in its social
and economic dimensions. Economics or social and economic dimen-
sions of a country are based on the health of people, their level of
education attainment and their standard of living [3].
2. Concerns on fundamental weaknesses and challenges
The efforts of World Health Organization (WHO) through consensus
resolutions, guidance documents, numerous series of workshops,
seminars and consultations, so far have not been fully translated to a
sustained awareness, solid infrastructure and reliable financing in all
countries. The US HHS PEPFAR project (Health and Human Service
President’s Emergency Plan for AIDS Relief) launched in 2004 and
implemented through Centers for Disease Control and Environment
(CDC) resulted unfortunately in many benefiting countries a still being
at or close to square one when funding was discontinued. [5,6] This
should urge development partners and donor agencies to analyse where
the root cause is and to identify the fundamental weaknesses and
challenges to create opportunities for establishing sustainably operating
blood systems build on an adequately functioning and collapse-proof
infrastructure in each and every country.
Fundamental weaknesses and challenges of the international blood
and bioproducts availability, transfusion safety and clinical efficacy in
poor economics are in the regulatory framework, governance and lea-
dership.
The 2010 WHA Resolution 63.12 [7] expressed concern about the
unequal levels of access globally to blood products, particularly plasma
derived medicinal products (PDMP). Such inequality leaves many pa-
tients without needed treatment and aggravates the national burden of
disease, both acquired and congenital. However, recently promising
research was published on plasma fractionation and virus inactivation
of cryoprecipitate in low- and medium-HDI countries [8,9]. Blood
transfusion is an integral supportive element of the health-care service
and deserves equal attention and efforts to accelerate the transition,
starting at supreme governance level. In 2012 the UN Resolution 67/81
Global Health Policy [10] recognized the responsibility of Governments
to urgently and significantly scale up efforts to accelerate the challenge
transition towards the opportunity to create universal access to af-
fordable and quality health-care services to achieve Universal Health
Coverage (UHC). UHC as pertains to blood and blood products, means
that all individuals and communities have access to affordable and
timely supplies of safe and quality-assured blood and blood product
[11].
With the WHA63.12 Resolution, World Health Assembly urged all
Member States ‘to take all the necessary steps to update their national
regulations on donor assessment and deferral, the collection, testing,
processing, storage, transportation and use of blood products, and op-
eration of regulatory authorities in order to ensure that regulatory
control in the area of quality and safety of blood products across the
entire transfusion chain meets internationally recognized standards’
[7]. Achieving self-sufficiency in the availability and supply of safe
blood is an important national goal in preventing blood and bio-product
shortages and meeting the transfusion needs of the patient population.
Consequently blood and blood components (whole blood, red cells,
platelets and fresh plasma) were included in the 18th edition of the core
list of WHO Model List of Essential Medicines in 2013 [12], where the
elementary in-vitro diagnostics were included in the 2018 first edition
of the Model List of Essential In Vitro Diagnostics. [13] To support
countries and interested supportive third parties in the development
and management of blood and blood components as essential medicines
the WHO Expert Committee on Biological Standardization published in
2017 practical guidelines which include a chapter on the blood reg-
ulatory system needed and a final recommendation on stepwise im-
plementation of a nationally regulated blood system [14].
3. Future perspectives on implementation of advanced
technologies
The theme of this 2020 series of special issues focuses on the ma-
nipulation and advanced preservation technologies and methodologies
like cryopreservation and freeze-drying of platelets, red cells, PDMPs and
mobilized pluripotent stem cells. These bio-products could be applied in
a variety of clinical situations e.g., hemato-oncology, thalassemia and
sickle cell disease, congenital coagulopathies and regenerative medicine.
However, a well-developed and sustained infrastructure is an absolute
prerequisite, including appropriate education and specialized skills to
implement and operate. In the advanced part of the world these pre-
requisites and fundamental conditions are taken for granted resulting in
reluctance to include the necessary considerations when attempting to
export the appropriate knowledge and science to less advanced parts of
the world. However, interestingly progress towards pathogen inactiva-
tion of whole blood, the general transfusion commodity in Sub-Saharan
Africa, has recently been published. [15]
Another paramount element is the need for standards and doc-
umentation in casu a well designed, comprehensive and operational
quality system management based on an established quality culture.
[16]
4. Where are we now, what then is the problem?
Over the past decades there has been increased interest in ensuring
the support of development and strengthening of availability and safety
of blood and blood products including the PDMPs and cellular bio-
products in low- and middle-income (LMI) or -HDI countries; the poor
economics. Governance and leadership are essential strategies, which
are generally lacking and must be addressed more stringently. Without
Governments, through their National Health Authorities, approving a
legal framework necessary for establishing an effective organisation
and quality managed blood service capable of meeting the needs of all
patients through each country; ensuring sustainable annual fiscal bud-
getary allocations; providing a reliable infrastructure and capacity for a
sustainable Blood Service, these aspirational recommendations of
Leadership and Governance to develop and implement, such advanced
technologies and methodologies will not be possible.
However, a slowly growing number of countries will reach a point
where the challenge of quality manipulation, cryopreservation and
freeze-drying of cellular components becomes an opportunity for im-
plementing specific health care visions, policies and strategies in line
with the Sustainable Development Goals 2016–2030 [17].
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